Novogene Co., Ltd.
Shanghai Stock Exchange 688315.SS
Novogene Co., Ltd. EBITDA for the year ending December 31, 2023: USD 52.03 M
-
Novogene Co., Ltd. EBITDA for the year ending December 31, 2022 was USD 49.71 M, a -18.55% change year over year.
-
Novogene Co., Ltd. EBITDA for the year ending December 31, 2021 was USD 61.03 M, a 152.24% change year over year.
-
Novogene Co., Ltd. EBITDA for the year ending December 31, 2020 was USD 24.19 M, a -21.45% change year over year.
-
Novogene Co., Ltd. EBITDA for the year ending December 31, 2019 was USD 30.80 M, a 6.09% change year over year.
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
Don’t Miss A Beat
| CEO | Dr. Ruiqiang Li |
| IPO Date | April 13, 2021 |
| Location | China |
| Headquarters | Building 301 |
| Employees | 2,144 |
| Sector | Healthcare |
| Industries | |
Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus, a next-generation sequencing based companion diagnostic assay for PARP inhibitor therapies; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples. Novogene Co., Ltd. has a strategic partnership with Hummingbird Bioscience Pte. Ltd. to support the development of investigational drug candidate HMBD-001, an anti-HER3 antibody to be evaluated for treatment of various tumor types, including NRG1-fusion driven cancers. The company was founded in 2011 and is headquartered in Beijing, China.
Past 5 years
USD 1.81
StockViz Staff
February 3, 2025
Any question? Send us an email